386 filings
8-K
EYEG
EyeGate Pharmaceuticals, Inc.
9 Aug 24
Kiora Pharmaceuticals Reports Second Quarter Results; Retinal Disease Drug Development Pipeline Advancing Toward Two Phase 2 Studies
7:01am
10-Q
2024 Q2
EYEG
EyeGate Pharmaceuticals, Inc.
Quarterly report
9 Aug 24
7:01am
8-K
EYEG
EyeGate Pharmaceuticals, Inc.
30 Jul 24
Kiora Pharmaceuticals Receives European Orphan Medicinal Product Designation for KIO-301 for the Treatment of Inherited Retinal Dystrophies
7:02am
8-K
EYEG
EyeGate Pharmaceuticals, Inc.
1 Jul 24
Biotech Executive Lisa Walters-Hoffert Joins Kiora Pharmaceuticals' Board of Directors
7:00am
8-K
EYEG
EyeGate Pharmaceuticals, Inc.
7 Jun 24
Material Modifications to Rights of Security Holders
7:02am
8-K
kllfbhhr4439zu0flyeh
10 May 24
Kiora Pharmaceuticals Reports First Quarter Results; Update on Pipeline of Drugs Targeting Retinal Disease
7:01am
S-8
ggthy4
10 May 24
Registration of securities for employees
6:59am
EFFECT
5l7c775n89solngb5
29 Mar 24
Notice of effectiveness
12:15am
424B3
kn3eo7eqhv0qb lzjdf
28 Mar 24
Prospectus supplement
4:48pm
8-K
bj8pwgwxrokggo
25 Mar 24
Results of Operations and Financial Condition
7:03am
D
04aazp8syd
14 Feb 24
$15.00 mm in equity / options / securities to be acquired, sold $15.00 mm, 13 investors
3:51pm
8-K
rrqlb11b7 xyqtn4de6x
12 Feb 24
Regulation FD Disclosure
5:23pm
8-K
b0fzmkzr5x js1risx
1 Feb 24
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million
7:01am
8-K
okllr9
31 Jan 24
Entry into a Material Definitive Agreement
5:14pm
8-K
yfaog8k0u2p tcx
16 Jan 24
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
5:16pm